*ST百花(600721.SH):擬將華威醫藥所持禮華生物及黃龍生物100%股權劃轉至公司
格隆匯5月28日丨*ST百花(600721.SH)公佈,為進一步理順公司股權架構和提升管理效率,根據公司中長期戰略發展規劃要求,結合產業現狀及發展佈局需要,經第七屆董事會第二十七次會議審議通過,公司擬對所屬公司的股權進行劃轉。
公司擬將華威醫藥所持江蘇禮華生物技術有限公司(“禮華生物”)及黃龍生物100%股權劃轉至公司;股權劃轉後,康緣華威成為華威醫藥參股公司,禮華生物及黃龍生物成為公司全資子公司。
此次股權劃轉的主要目的是通過股權劃轉提升管理效率,助推公司在醫藥大健康的產業佈局,有利於更好地實現公司的戰略發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.